Close

B-LCL, Donor 228 (ICZP275)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

B Lymphoblastoid Cell lines are derived by infection of PBMC with Epstein-Barr virus. The virus immortalizes B lymphocytes. It typically is not shed from cells but cultures should still be handled under Biosafety level 2 conditions.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • B-LCL, Donor 228
  • Cat. No.
  • ICZP275
  • Gender
  • Male
  • Donor Age
  • 34
  • HLA-A
  • HLA-A: 02:01,30
  • HLA-B
  • HLA-B: 18,44
  • HLA-C
  • HLA-C: 05,05
  • HLA-DRβ1
  • HLA-DRβ 1: 15,03
  • Blood Type
  • Unknown
  • Ethnicity
  • Caucasian
  • Additional Donor Information
  • Healthy male 5' 10″ tall, 185 lbs.

Additional Information

  • Cell Purity
  • >95%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
  • Sterility Testing
  • Creative Biolabs provides sterility testing in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
  • Genetic Stability Testing
  • We perform cell genetic stability studies under ICH guidelines. We can provide guidance on the appropriate testing program upon your requirements.
  • Preparation
  • B Lymphoblastoid Cell lines are derived by infection of PBMC with Epstein-Barr virus. The virus immortalizes B lymphocytes. It typically is not shed from cells but cultures should still be handled under Biosafety level 2 conditions.
  • Application
  • Flow Cytometry; MAT assays
  • Research Use Only
  • Our recombinant Jurkat cell are for research use only, not for diagnostic or therapeutic use.
  • Quality Control
  • Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification). Growth media are also certified based on U.S. Public Health Service Guidelines.
  • Storage
  • vapour phase nitrogen
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Warnings
  • Avoid multiple freeze/thaw cycles
  • Size
  • 1-5M cells/vial
  • Keywords
  • ICZP275; B-LCL, Donor 228; B-LCL

Customer Reviews and Q&As

There are currently no customer reviews or questions for B-LCL, Donor 228 (ICZP275). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.